Results 21 to 30 of about 54,427 (263)

Involving young people in research investigating comorbidity associated with childhood-onset rheumatic disease: perspectives of a series of focus groups [PDF]

open access: yesBMC Rheumatology
Background Childhood-onset rheumatic diseases, such as juvenile idiopathic arthritis, juvenile-onset lupus and juvenile dermatomyositis, appear to be associated with an increased risk of comorbidities in adulthood compared to the general population.
Sab Siddiq   +6 more
doaj   +2 more sources

Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study [PDF]

open access: yesLupus, 2021
Introduction Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease with significant morbidity and mortality. Neuropsychiatric (NP) involvement is a severe complication, encompassing a heterogeneous range of neurological and psychiatric manifestations.
Giani, Teresa   +26 more
openaire   +6 more sources

Abstract 13 — Comparison of Clinical and Serological Features in Juvenile and Adult-Onset Systemic Lupus Erythematosus

open access: yesJournal of Clinical Rheumatology and Immunology, 2023
Background Systemic lupus erythematosus (SLE) has varying clinical and serological features in juvenile and adult-onset disease groups, depending on the ethnicity. Objectives: To compare the disease characteristics of patients with adult-onset (ASLE) and
Babur Salim   +4 more
doaj   +1 more source

The role of assessment of renal biopsy in electron microscopy in making a diagnosis of juvenile-onset systemic lupus erythematosus in a 16-year-old female patient with depression and proteinuria – case report

open access: yesCentral European Journal of Immunology, 2022
The course of juvenile-onset systemic lupus erythematosus may vary, from rapid multiorgan involvement to insidious development mimicking different medical conditions.
Tomasz Koszutski   +4 more
doaj   +1 more source

Rituximab therapy for juvenile-onset systemic lupus erythematosus [PDF]

open access: yesPediatric Nephrology, 2007
Rituximab (RTX), an anti-CD20 monoclonal antibody, has been proposed for use in the therapy of systemic lupus erythematosus (SLE). We present the initial long-term experience of the safety and efficacy of rituximab for treatment of SLE in children.
Nwobi, Obioma   +4 more
openaire   +2 more sources

Investigating biomarkers of disease activity in juvenile-onset lupus nephritis [PDF]

open access: yesRheumatology, 2014
E. Smith   +6 more
semanticscholar   +2 more sources

Juvenile-onset multifocal osteonecrosis in systemic lupus erythematosus

open access: yesMedicine, 2021
Abstract Rationale: Osteonecrosis (ON) is a devastating illness that leads to bone ischemia and potential joint destruction. Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease, with multi-system involvement which is closely associated with occurrence of ON.
Jin, Wenyuan, Yang, Xinghui, Lu, Meiping
openaire   +2 more sources

What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematous Since Development of the SHARE Recommendations 2012?

open access: yesFrontiers in Pediatrics, 2022
IntroductionJuvenile-onset systemic lupus erythematous (JSLE) is a rare multisystem autoimmune disorder. In 2012, the Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) initiative developed recommendations for the diagnosis ...
Kathy L. Gallagher   +5 more
doaj   +1 more source

An unusual presentation of juvenile lupus nephritis

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2016
The incidence of juvenile lupus varies widely ranging between 4 and 250 per 100,000 population. Most common organ involvement in juvenile lupus is kidney. Neurological, cutaneous and hematological involvements are also involved.
Malleshwar Bottu   +3 more
doaj   +1 more source

Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature [PDF]

open access: yes, 2015
Macrophage activation syndrome (MAS) is a potentially fatal condition. It is a rare complication of several autoimmune disorders, including systemic lupus erythematosus (SLE) and systemic juvenile idiopathic arthritis (sJIA).
Didona, Dario   +4 more
core   +4 more sources

Home - About - Disclaimer - Privacy